OPKO bags US’ No 3 clinical lab operator for $1.47bn
This article was originally published in Clinica
Executive Summary
OPKO Health has agreed to acquire Bio-Reference Laboratories (BRL), the third largest full-service clinical laboratory in the US with a strong focus on genetic testing, in an all-stock deal worth $1.47bn. The deal will provide Miami-based OPKO with an extensive US sales and distribution network through which it can commercialize its recently launched 4Kscore test, for predicting the risk of aggressive prostate cancer, and other diagnostics tests from OPKO’s pipeline.
You may also be interested in...
The Frost Factor: An M&A Leader's Standout Strategy For Opko Health
With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.